As the anti-tumor effects of most of the here-identified drug candidates involve activation of p53, we determined the effects on p53 signaling upon short-term exposures to selected drugs in the KMT2A-rearranged ALL cell lines RS4;11 and ALL-PO. The gene discussed is TP53; the disease is neoplasm.